HD Labs TIRSEMA 44 – Tirzepatide 40 mg + Semaglutide 4 mg
Dual-Pathway Metabolic & Weight-Management Injection
TIRSEMA 44 is a combination injectable formulation containing Tirzepatide (40 mg) and Semaglutide (4 mg), presented in a pre-filled subcutaneous injection pen. This advanced dual-compound product is designed to support comprehensive metabolic signalling by engaging GLP-1–based pathways alongside Tirzepatide’s broader metabolic activity.
By combining two well-established incretin-based agents, TIRSEMA 44 offers a synergistic approach to appetite regulation, glycaemic control, and metabolic optimisation within supervised clinical or medical use settings.
Therapeutic Focus
Appetite and satiety regulation
Weight-management support
Blood glucose and insulin signalling control
Enhanced metabolic efficiency
Reduced caloric intake via central appetite mechanisms
Product Information
Active Ingredients:
Tirzepatide – 40 mg
Semaglutide – 4 mg
Form: Solution for injection
Delivery System: Pre-filled injection pen
Route of Administration: Subcutaneous
Use: Single-patient use only
Quality & Manufacturing
Pharmaceutical-grade formulation
Precision-filled for accurate dosing
Manufactured under controlled quality standards
Designed for stability, consistency, and ease of use